Integrated Quantitative Investments LLC Makes New Investment in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Integrated Quantitative Investments LLC acquired a new stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 116,500 shares of the company's stock, valued at approximately $1,840,000. Dr. Reddy's Laboratories makes up 0.9% of Integrated Quantitative Investments LLC's investment portfolio, making the stock its 5th biggest position.

Several other institutional investors have also modified their holdings of the company. EverSource Wealth Advisors LLC boosted its holdings in shares of Dr. Reddy's Laboratories by 423.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock valued at $29,000 after buying an additional 1,507 shares in the last quarter. POM Investment Strategies LLC grew its holdings in shares of Dr. Reddy's Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after purchasing an additional 1,820 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Dr. Reddy's Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after purchasing an additional 2,093 shares during the last quarter. Independence Bank of Kentucky increased its position in shares of Dr. Reddy's Laboratories by 400.0% during the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock worth $44,000 after purchasing an additional 2,220 shares in the last quarter. Finally, Allworth Financial LP boosted its position in shares of Dr. Reddy's Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company's stock valued at $41,000 after purchasing an additional 2,230 shares during the period. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy's Laboratories Stock Performance

Shares of RDY stock traded down $0.07 during midday trading on Wednesday, hitting $12.37. The company had a trading volume of 1,458,093 shares, compared to its average volume of 1,371,368. The stock has a market cap of $10.32 billion, a price-to-earnings ratio of 19.72 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company's 50 day simple moving average is $13.26 and its 200 day simple moving average is $14.43. Dr. Reddy's Laboratories Limited has a 52-week low of $12.18 and a 52-week high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Nomura cut shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.